We reported previously that Pin1 facilitates human immunodeficiency virus type 1 (HIV-1) uncoating by interacting with the capsid core through the phosphorylated Ser 16 -Pro 17 motif. However, the specific kinase responsible for Ser 16 phosphorylation has remained unknown. Here, we showed that virion-associated extracellular signal-regulated kinase 2 (ERK2) phosphorylates Ser 16 . The characterization of immature virions produced by exposing chronically HIV-1 LAV-1 -infected CEM/LAV-1 cells to 10 mM saquinavir indicated that Ser 16 is phosphorylated after the initiation of Pr55 Gag processing. Furthermore, a mass spectrometry-based in vitro kinase assay demonstrated that ERK2 specifically phosphorylated the Ser 16 residue in the Ser 16 -Pro 17 motif-containing substrate. The treatment of CEM/LAV-1 cells with the ERK2 inhibitor sc-222229 decreased the Ser 16 phosphorylation level inside virions, and virus partially defective in Ser 16 phosphorylation showed impaired reverse transcription and attenuated replication owing to attenuated Pin1-dependent uncoating. Furthermore, the suppression of ERK2 expression by RNA interference in CEM/LAV-1 cells resulted in suppressed ERK2 packaging inside virions and decreased the Ser 16 phosphorylation level inside virions. Interestingly, the ERK2-packagingdefective virus showed impaired reverse transcription and attenuated HIV-1 replication. Taken together, these findings provide insights into the as-yet-obscure processes in Pin1-dependent HIV-1 uncoating.
INTRODUCTION
An early and critical event in the human immunodeficiency virus type 1 (HIV-1) life cycle is uncoating of the viral core. We reported previously that uncoating requires an interaction of the capsid CA protein with the peptidylprolyl isomerase Pin1, which recognizes the phosphorylated Ser 16 residue followed by Pro 17 (Misumi et al., 2010) . To investigate how the Ser 16 -Pro 17 motif of the CA protein is phosphorylated, Western blotting with an anti-pS16/P17 antibody was carried out, which demonstrated that Ser 16 is phosphorylated inside HIV-1 strain LAV-1 (HIV-1 LAV-1 ) virions but not inside cells of the chronically HIV-1 LAV-1infected T-cell line CEM/LAV-1, although the specific kinase that phosphorylates Ser 16 was unknown (Misumi et al., 2010) . Therefore, we investigated which Ser/Thr kinase phosphorylates Ser 16 inside virions.
As the HIV-1 genome only encodes a limited number of viral proteins, HIV-1 must take advantage of the multiple functions of host proteins for successful replication. Several studies of purified HIV-1 virions have shown that, in addition to proteins encoded by the virus, host proteins are found inside virions (Ott, 1997) . Some of these proteins may be taken into virions simply because of their proximity to the viral assembly and budding sites, whilst other host proteins, such as cyclophilin A and lysyl-tRNA synthetase (LysRS), are incorporated into virions as a result of their interaction with Gag proteins during viral assembly (Franke et al., 1994; Thali et al., 1994; Ott et al., 1995; Cen et al., 2001; Gabor et al., 2002) . These host proteins play important roles in Gag protein folding and tRNA Lys3 packaging. Furthermore, other studies have demonstrated that host-cell Ser/Thr kinases such as extracellular signalregulated kinase 2 (ERK2) and the catalytic subunit of cyclic AMP-dependent protein kinase A (PKA) are also incorporated into virions (Cartier et al., 1997; Jacqué et al., 1998; Cartier et al., 2003) . ERK2 was the first protein kinase of cellular origin to be detected inside virions (Cartier et al., 1997) . Recently, Gupta et al. (2011) reported that ERK-2 is incorporated into virions owing to its interaction with the CA region of the structural protein Gag. Furthermore, Jacqué et al. (1998) reported that the impairment of host-cell ERK-2 activity by synthetic inhibitors results in reduced HIV infectivity. In contrast, Cartier et al. (2003) reported that PKA phosphorylates the CA protein, and that viruses produced from PKA-deficient cell lines are not infectious. These findings support the hypothesis that a virion-associated kinase contributes to the phosphorylation of Ser 16 inside virions.
In this study, we showed that ERK2 was incorporated into virions and that the reduction in the enzymic activity of ERK2 or the suppression of ERK2 packaging into virions decreased the Ser 16 phosphorylation level inside virions and viral infectivity through attenuated Pin1-dependent uncoating. These findings elucidate the virus replication capacity gained by ERK2 packaging and reveal a novel regulation step of HIV-1 infection.
RESULTS

Detection of phosphorylated Ser 16 in CA protein
We demonstrated previously that Ser 16 is phosphorylated inside HIV-1 LAV-1 virions but not inside CEM/LAV-1 cells (Misumi et al., 2010) . To investigate further how Ser 16 in the CA protein is phosphorylated in the HIV-1 life cycle, CEM/ LAV-1 cells were treated with the HIV-1 protease (PR) inhibitor saquinavir. The resulting HIV-1 LAV-1 virions were lysed, and the lysate (20 mg protein) was subjected to Western blotting using an HIV-positive plasma, an anti-CA antibody or an anti-pS16/P17 antibody, which recognizes the CA-derived epitope containing phosphorylated Ser 16 (HQAIpS 16 P 17 RTLN) but does not bind to the non-phosphorylated CA protein treated with alkaline phosphatase (ALP) (Misumi et al., 2010) . As shown in Fig. 1(a, b) , the normal pattern of PR-mediated Gag processing without saquinavir (0 mM) was observed. In contrast, treatment with saquinavir (10 mM) caused the accumulation of Pr55 Gag and Gag polyprotein intermediates (p41, p45) inside HIV-1 LAV-1 virions (Fig. 1a, b ). Interestingly, in the absence of saquinavir, the CA protein and Gag polyprotein intermediates were phosphorylated at the Ser 16 residue but Pr55 Gag was not phosphorylated (Fig. 1c ). Furthermore, Pr55 Gag was not phosphorylated at the Ser 16 residue even when Pr55 Gag and Gag polyprotein intermediates accumulated in the presence of saquinavir (Fig. 1c ). The results suggested that Ser 16 in the CA protein is phosphorylated following the initiation of virion maturation and that a specific kinase should be incorporated inside virions for Ser 16 phosphorylation.
ERK2 specifically phosphorylates Ser in the Ser-Pro motif-containing substrate derived from CA protein
To obtain insight into the mechanism of Ser 16 phosphorylation, we performed an in vitro kinase assay using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry. The CA-derived Ser-Pro motif-containing substrate was incubated with each of the Ser/ Thr kinase candidates (i.e. CDK4, CDK5, CDK7, ERK1, ERK2, p38a, p38b, PKA and PKC). The subset of Ser/Thr kinases was deduced using the kinase substrate prediction algorithm from the primary structure of CA-derived Ser-Pro motif-containing substrate (Carna Biosciences), and the resulting phosphorylated product was detected. As shown in Fig. 2 (a, upper panel), specific Ser phosphorylation of the substrate was detected in the presence of ERK2 because the mass spectrum corresponding to the phosphorylated form of the substrate showed the typical isotope distribution and exhibited a peak at m/z 1698.97, suggesting that ERK2 phosphorylates Ser 16 inside virions. In contrast, the substrate containing S16A/P17A mutation was not phosphorylated ( Fig. 2a 
Cellular Ser/Thr protein kinase ERK2 is incorporated in HIV-1 particles
We next examined whether ERK2 could be packaged inside virions for Ser 16 phosphorylation. The amount of ERK2 inside the HIV-1 particles has not been reliably determined owing to contamination of virus preparations by microvesicles containing host-cell proteins. Therefore, we used a CD45-based immunoaffinity depletion method for removing CD45-containing [CD45(+)] microvesicles, which yields highly purified preparations of virions. CD45 is found on microvesicles, yet appears to be excluded from HIV-1 particles (Trubey et al., 2003) . As shown in Fig. 2 (b, lower panel), most of the CD45(+) contaminating particles such as microvesicles and exosomes were removed from the starting material because no CD45 signal was detected in the lane of the CD45-depleted [CD45(2)] fraction. Western blot analysis for ERK2 and CA protein indicated that ERK2 was incorporated into not only the microvesicle-depleted HIV-1 LAV-1 preparation but also microvesicles ( Fig. 2b , lower panel). Interestingly, the phosphorylated form of ERK2 (pTyr 187 or pThr 185 -pTyr 187 ) was effectively packaged inside microvesicle-depleted HIV-1 LAV-1 virions [CD45(2) fraction]. Furthermore, we performed immunogold labelling in electron microscopy experiments to observe an individual virus particle because it is difficult to remove CD45(+) contaminating particles completely from the HIV preparations. As shown in Fig. 2 (c, middle panel), immunogold particles were found on the core and on the envelope, suggesting that ERK2 exists in the virion. Furthermore, some immunogold particles were found in the budding form of virions from infected cells, and a characteristic high-density Gag layer was found underneath the viral membrane ( Fig. 2c , lower panel). In contrast, to determine the amount of labelling due to non-specific binding of the gold-labelled secondary antibodies, sections were stained with the goldconjugated secondary antibodies in the presence of control mouse IgG (Fig. 2c, upper panel) . As shown in Fig. 2 (c, upper panel), no gold labelling was observed. The immunogold staining of ERK2 indicated that ERK2 is incorporated into newly formed viral particles via its interaction with the Gag polyprotein Pr55 Gag (Fig. 2c , lower panel). These findings suggested that ERK2 phosphorylates Ser 16 inside virions.
A decrease in ERK2 activity in HIV-1 LAV-1producing cells is accompanied by decreases in the level of Ser 16 phosphorylation inside virions and viral infectivity
To determine whether a decrease in ERK2 activity in CEM/ LAV-1 cells affects Ser 16 phosphorylation and viral infectivity, CEM/LAV-1 cells were treated with the ERK2 inhibitor sc-222229. As shown in Fig. 3(a) , no significant cytotoxicity of sc-222229 at a concentration of 100 nM was observed. HIV-1 virions were harvested from supernatants of CEM/LAV-1 cells treated with sc-222229 in the range 0-100 nM and the level of virus production was determined from the amount of CA protein in supernatants.
Fig. 3(b)
shows that treatment with sc-222229 did not affect virus production by CEM/LAV-1 cells (Fig. 3b ). To demonstrate further the effect of virions obtained from sc-222229-treated cells on viral entry, we isolated the cytosolic and vesicular fractions of target cells post-infection, as described previously by Maréchal et al. (1998) , who reported that the measurement of cytosolic p24 after virus infection is a reliable assay for the assessment of virus entry events leading to authentic cell infection. The viral entry assay indicated that the entry level of viruses obtained from sc-222229-treated CEM/LAV-1 cells was comparable to that of the control CA protein in the cytosolic fraction (Fig.  3c ). The resulting HIV-1 LAV-1 virions obtained from sc-222229-treated CEM/LAV-1 cells were lysed, and the lysate (20 mg protein) was separated by SDS-PAGE in parallel on two different gels and subsequently subjected to Western blotting using anti-CA antibody or anti-pS16/P17 antibody. Interestingly, treatment with sc-222229 specifically decreased the Ser 16 phosphorylation level inside virions in a concentration-dependent manner (Fig. 3d ). The Ser 16phosphorylation-defective virus showed a significant decrease in the level of the late viral cDNA product in a concentration-dependent manner but not in that of the early viral cDNA (Figs 3e, f, P,0.01). The virus also showed a decrease in infectivity compared with the control virus produced by CEM/LAV-1 cells not treated with sc-222229 ( Fig. 3g , P,0.01). To clarify further whether the suppressed Ser 16 phosphorylation suppressed Pin1dependent uncoating, we attempted to study the process in vitro by detecting the disassembly of the CA core in the presence of Pin1 in accordance with previously described methods (Misumi et al., 2010) . As shown in Fig. 4 (a, left panel), disassembly of the wt CA core (core wt ) was dependent on Pin1. Consistent with previous data (Misumi et al., 2010) , Pin1-dependent uncoating was blocked by dephosphorylation of the core wt with ALP ( Fig.  4a , right panel). Partial Ser 16 -phosphorylation-defective CA cores (core sc ) from viruses produced from sc-222229treated CEM/LAV-1 cells were also purified and then incubated with glutathione S-transferases (GST)-Pin1. As shown in the Fig. 4 (b) left panel, the uncoating of Ser 16phosphorylation-defective CA cores (core sc ) was partially attenuated. Furthermore, the relative percentage of disassembly efficiency of core sc further treated with ALP in the presence of GST-Pin1 was comparable to that of the core sc further treated with inactivated ALP in the absence of GST-Pin1, suggesting that uncoating of core sc was completely blocked by the further treatment with ALP ( Fig. 4b, right panel) . These findings suggested that the Pin1-dependent CA core dissociation was attenuated by the suppressed Ser 16 phosphorylation of the CA core.
ERK2-packaging-defective virus exhibits lower infectivity than control virus
To determine whether a decrease in the packaging level of virion-associated ERK2 affects HIV-1 infectivity, we transfected CEM/LAV-1 cells with validated commercially (e, f) Reverse transcription products were determined by quantitative PCR analysis using early-stage primers (R/U5) and late-stage primers (R/gag), as described in Methods. The following computations were used to determine the amount of the individual DNA forms: (e) the copy number of the early viral cDNA5R/U5 DNA copies"R/gag DNA copies; (f) the copy number of the late viral cDNA5R/gag DNA copies. To normalize the amount of cellular DNA (50 ng) in the available Stealth ERK2 small interfering RNA (siRNA) or control siRNA. As shown in Fig. 5(a) , ERK2 siRNA significantly decreased the ERK2 level inside CEM/LAV-1 cells without altering the levels of ERK1 and actin. To confirm whether the packaging level of virion-associated ERK2 was decreased by ERK2 siRNA treatment, highly purified viral preparations were obtained by CD45 immunoaffinity depletion. Fig. 5(b) indicates that the viral preparations were highly purified because no CD45 signal was detected in the lane of the CD45(2) fraction. Therefore, the lysates of the microvesicle-depleted HIV-1 LAV-1 preparations [CD45(2) fractions] were separated by SDS-PAGE in parallel on different gels and subsequently subjected to Western blotting using anti-ERK2 antibody, anti-phosphorylated ERK2 antibody (dual phospho-Thr 185 /Tyr 187 ), HIV-positive plasma or anti-pS16/P17 antibody. ERK2 siRNA specifically decreased the levels of ERK2 and phosphorylated ERK2 (pThr 185 -pTyr 187 ) inside virions (Fig. 5c, d) without altering the level of the CA protein ( Fig. 5e ) and further decreased the Ser 16 phosphorylation level inside virions (Fig. 5f ). Therefore, we investigated whether the infectivity of the ERK2-packaging-defective virus also decreased. Interestingly, the ERK2-defective virus showed decreased infectivity compared with the control virus ( Fig. 5g , P,0.01). To clarify further the relationship between the decreased infectivity of the ERK2-defective virus and reverse transcription efficiency, we carried out quantitative real-time PCR analysis using primers designed to specifically amplify the late products of reverse transcription. The ERK2-defective virus showed a significant decrease in the level of the late (R/gag) viral cDNA product ( Fig. 5h , P,0.05). These findings suggested that virion-associated ERK2 is necessary for the maintenance of infectivity.
DISCUSSION
Uncoating of the viral core immediately after entry into a target cell is a critical event in the HIV-1 life cycle. The HIV-1 CA protein must assemble properly and disassemble to allow genomic RNA release after fusion. Because both assembly and disassembly cannot occur in the CA protein simultaneously, it is important to determine the mechanisms underlying the switch from assembly to disassembly. Thus, we demonstrated previously that phosphorylation of the HIV-1 CA protein at Ser 16 acts as a 'molecular trigger' of Pin1-dependent HIV-1 uncoating (Misumi et al., 2010) . We also showed (Misumi et al., 2010) that an HIV-1 CA mutant (S16A/P17A) that cannot be phosphorylated at Ser 16 shows an impaired uncoating process in target cells. However, little has been known about the mechanism and timing of Ser 16 phosphorylation inside virions. Some studies have shown that proper and regulated uncoating of the viral core is crucial to subsequent steps such as reverse transcription and nuclear import in the viral life cycle (Fitzon et al., 2000; Forshey et al., 2002; Dismuke & Aiken, 2006; Leschonsky et al., 2007) and that changes in the timing of uncoating block viral infection (Forshey et al., 2002) . Therefore, we hypothesized that Ser 16 phosphorylation also occurs inside virions in a temporally regulated manner. In this study, we demonstrate that Ser 16 is phosphorylated inside virions after the initiation of Pr55 Gag processing, suggesting that Ser 16 is masked or sterically hindered prior to the initiation of Pr55 Gag processing owing to Pr55 Gag multimerization during HIV-1 assembly. Furthermore, if p41 and p45 (Fig. 1b ) are the sources of CA phosphorylated at Ser 16 , why are p41 and p45 phosphorylated to a greater extent ( Fig. 1b) ? Rue et al. (2005) reported that the domains of incompletely cleaved CA are phosphorylated to a greater extent than those of free (completely cleaved) CA in virions of simian immunodeficiency virus, although it is unclear whether Ser 16 is actually phosphorylated. These findings indicate that Ser 16 of CA is phosphorylated by ERK2 and then dephosphorylated by a virion-associated phosphatase before the completion of CA cleavage. Identification of the phosphatase incorporated into HIV virions would greatly facilitate the determination of events occurring in budded virus.
To obtain further insights into the mechanism of Ser 16 phosphorylation inside virions, we next determined the Ser/Thr kinase that can phosphorylate Ser 16 . An in vitro kinase assay suggested that ERK2 can phosphorylate Ser 16 inside virions ( Fig. 2a ). Furthermore, we examined whether ERK2 could directly phosphorylate the recombinant CA protein (BioAcademia). Recombinant CA protein was incubated with the recombinant enzyme-activated ERK2, Mg 2+ and ATP at 37 u C. After incubation, the recombinant CA protein was purified and detected by MALDI-TOF mass spectrometry. However, no phosphorylated form of the recombinant CA protein was detected (data not shown), suggesting that formation of the N-terminal b-hairpin of CA or the normal folding of the capsid protein renders the ERK2 interaction with the recombinant CA protein difficult. As shown in Fig. 1(b Role of ERK2 in HIV-1 uncoating 1996) and p6 (Müller et al., 2002; Hemonnot et al., 2004) , which are involved in the early phase of the life cycle of HIV-1 and in virus production. Regarding Vif, Yang & Gabuzda (1998) showed that the ERK2-mediated Vif phosphorylation at Thr 96 has no effect on virus replication in Vif-permissive cells such as SupT1 cells. As shown in Fig.  3(g) , the Ser 16 phosphorylation-defective virus showed a decreased infectivity in TZM-bl cells, which do not require Vif for HIV-1 replication, suggesting that the inhibition of phosphorylation of proteins other than Vif contributes to a decreased infectivity.
In contrast, Bukrinskaya et al. (1996) reported that at least five serine phosphate acceptor sites in the MA protein are utilized by the virion-associated Ser/Thr kinase. To elucidate the biological significance of MA protein phosphorylation, they introduced individual amino acid substitutions (SerAAla) at all conserved serine residues of the MA protein (including S 38 , S 67 , S 72 , S 77 and S 111 ). The infectivity of all the single mutants in CD4 + MT4 cells was equal to that of wt HIV-1 (Bukrinskaya et al., 1996) , suggesting that the inhibition of ERK2-mediated phosphorylation of viral proteins other than the MA protein decreases infectivity. Furthermore, an HIV-1 CA mutant (S16A/P17A) shows markedly decreased infectivity owing to the dysfunction of its uncoating process despite all the phosphorylatable serine residues of the MA protein (including S 38 , S 67 , S 72 , S 77 and S 111 ) being conserved (Misumi et al., 2010) , suggesting that the effects of ERK2 chemical inhibition or depletion are not due to the inhibition of MA protein phosphorylation in the virions.
Finally, regarding p6, Müller et al. (2002) and Hemonnot et al., (2004) reported that the HIV-1 p6 protein is phosphorylated by ERK2 in the context of both a Gag polyprotein precursor and a mature protein packaged within HIV-1 virions. Furthermore, Hemonnot et al. (2004) observed that alanine substitution of the unique phosphoacceptor Thr 23 identified in p6 significantly inhibits viral particle release and results in the accumulation of immature virions at the plasma membrane of the host cell. Fig. 3(b and d) shows that treatment with the ERK2 inhibitor sc-222229 decreased the Ser 16 phosphorylation level inside virions in a concentration-dependent manner without affecting the viral particle release. Therefore, it is not conceivable that the effects of ERK2 chemical inhibition or depletion are due to inhibition of ERK2-mediated phosphorylation of Vif, MA and p6 proteins other than the CA protein.
In summary, as shown in Fig. 6 , Ser 16 phosphorylation inside virions is catalysed by virion-incorporated ERK2 following the initiation of virion maturation (during Gag processing), suggesting that virion-incorporated ERK2 is involved in the early steps of HIV-1 replication by supporting the proper and regulated Pin1-dependent uncoating of the viral core that is crucial to subsequent steps such as reverse transcription and nuclear import in the viral life cycle. 
METHODS
Cell culture. A chronically HIV-1 LAV-1 -infected T-cell line (CEM/ LAV-1) was maintained at 37 uC in RPMI 1640 supplemented with 10 % FCS containing 100 IU penicillin ml 21 and 100 mg streptomycin ml 21 in 5 % CO 2 . Saquinavir and the sc-222229 inhibitor were separately dissolved in DMSO to make concentrated stock solutions (saquinavir, 50 mM; sc222229, 5 mM) and then diluted in RPMI 1640 to the specified working concentrations. TZM-bl cells were obtained from the NIH AIDS Research and Reference Reagent Program. This is a HeLa cell clone that has been engineered to express CD4 and CCR5 and contains integrated reporter genes for firefly luciferase and Escherichia coli b-galactosidase under control of an HIV-1 long terminal repeat, permitting sensitive and accurate measurements of infection.
Virus preparation. HIV-1 LAV-1 was prepared as described previously (Misumi et al., 2010) with slight modifications. The supernatant from the culture medium of CEM/LAV-1 cells with or without 10 mM saquinavir or the ERK2 inhibitor sc-222229 was filtered through a 0.45 mm pore-size disposable filter and then centrifuged at 43 000 g for 3 h at 4 uC. The obtained pellet was resuspended in PBS(2) (0.02 % KH 2 PO 4 , 0.29 % Na 2 HPO 4 .12H 2 O, 0.8 % NaCl, 0.02 % KCl) and then centrifuged at 100 000 g for 1 h at 4 uC. The resulting pellet was resuspended in 10 mM Tris/HCl buffer (pH 8.0) or PBS(2). To remove microvesicles, virions were subjected to CD45 immunodepletion with anti-CD45 paramagnetic microbeads, as described previously (Ott, 2009 ). HIV-1 preparations containing virions were incubated with 2 ml pre-washed CD45 microbeads (Miltenyi Biotech) per 1 mg total protein overnight on ice. The mixture of sample/CD45 microbeads was then applied to a washed and magnetized MACS separation column (Miltenyi Biotech). The flow-through fraction was collected to produce the CD45-depleted fraction. The column was then washed thoroughly with PBS(2). To recover the microvesicles retained on the beads as the CD45-bead fraction, pre-heated (95 uC) SDS gel loading buffer [62.5 mM Tris/HCl (pH 6.8), 2 % SDS, 10 % glycerol] was applied to the column matrix. LAV-1 cells treated with or without 10 mM saquinavir was subjected to SDS-PAGE using 5-20 % polyacrylamide gels in accordance with the method of Laemmli (1970) . Electrophoresis was carried out at 20 mA per gel for 90 min. Separated proteins were then transferred onto PVDF membranes at 80 mA cm 22 for 70 min. The membrane was saturated in 5 % skimmed milk powder in TBS [10 mM Tris/ HCl (pH 7.5), 0.5 M NaCl] and incubated for 4 h with each primary antibody (HIV-positive plasma, anti-CA antibody; ViroGen) and anti-pS16/P17 mAb (Misumi et al., 2010) . After washing in TBS-T (TBS plus 0.5 % Tween 20), the membrane was further incubated for 1 h with each secondary antibody and revealed using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific).
In vitro kinase assay. A dodecapeptide (H 2 N-HQAISPRTLNKK-COOH) was synthesized using an automatic peptide synthesizer. The peptide consisted of CA-derived linear decapeptide (H 2 N-H 12 QAISPRTLN 21 -COOH) and a dilysine motif to improve solubility, and was biotinylated at the a-amino group to introduce a biotin tag specifically at the N terminus. The dodecapeptide was incubated with each of the recombinant enzymic activated kinases (CDK4/cyclin D3, CDK5/p25, CDK7/cyclin H/MAT1, ERK1, ERK2, p38a, p38b, PK, and PKC), Mg 2+ and ATP at 37 uC in accordance with the kit protocol (Carna Biosciences). After incubation, the phosphorylated decapeptide was purified using ZipTip (Nihon Millipore) and determined by MALDI-TOF mass spectrometry (Bruker Daltonics). A mutant dodecapeptide (H 2 N-HQAIAARTLNKK-COOH), which contained an alanine substitution at the conserved Ser-Pro motif and was biotinylated at the N terminus, was used as a control peptide.
Detection of ERK2 inside virions. To detect ERK2 inside CEM/ LAV-1 cells and HIV LAV-1 , lysates of CEM/LAV-1 cells or virus preparations purified by anti-CD45 immunoaffinity depletion of microvesicles were subjected to Western blotting using an anti-CD45 antibody (H-230; Santa Cruz Biotechnology), an anti-ERK2 antibody (R&D Systems), an anti-phosphorylated ERK2 antibody (phospho-Tyr 187 ) (Assay Biotechnology Company), an anti-phosphorylated ERK2 antibody (dual phospho-Thr 185 /Tyr 187 ) (Cell Signaling Technology) and HIV-positive plasma. To confirm ERK2 packaging levels, Western blotting was carried out using a chemiluminescence protocol.
HIV-acutely infected CEM cells were fixed with 0.15 M PBS (pH 7.2) containing 1 % glutaraldehyde at 4 uC for 3 h. After dehydrating with serially graded ethanol, the samples were embedded in Lowicryl K4M resin (Electron Microscopy Science). Polymerization was allowed to occur in a UV irradiator (Dosaka EM) at 230 uC for 2 days and then at room temperature for 3 days. Ultrathin sections were cut using a Porter Blum Ultramicrotome (Sorvall MT-5000; Du Pont) and mounted on a nickel grid (300 mesh) supported by a carbon-coated collodion film. An immunolabelling technique was performed using the protocol of Hong et al. (2003) with modifications. Ultrathin sections on the grid were treated with 5 % normal goat serum in 0.15 M PBS (pH 7.2) to block non-specific reactions. Sections were then stained with mouse anti-ERK2 antibody (Millipore Corporation) (primary antibody) and then 5 nm gold-labelled anti-mouse IgG goat serum. Sections were first reacted by adding drops of the primary antibody at 37 uC for 3 h and washed three times in PBS. Sections were then allowed to react with the secondary antibody at 37 uC for 1 h and were subsequently washed three times in PBS. Finally, sections were contrast enhanced with a mixture of ruthenium red and osmium tetroxide solution and stained with uranyl acetate aqueous solution, as described previously (Kohno et al., 1998) , with some modifications. All procedures for contrast enhancement were performed at room temperature. All sections were observed under a transmission electron microscope (H-7650; Hitachi).
Viral entry assay. The entry level of viruses obtained from sc-222229-treated CEM/LAV-1 cells was determined as follows. A viral entry assay was performed using the protocol of Maréchal et al.
(1998) with modifications. Briefly, 250 ng virions obtained from CEM/LAV-1 cells treated with or without sc-222229 was used for virus inoculation, and the virions were incubated with TZM-bl cells (6610 6 cells per 75 cm 2 flask) at 4 uC for 30 min, and then incubated further for 4 h at 37 uC. The cells were treated with 1 ml ice-cold PBS(2) and incubated for 10 min at 4 uC in PBS (2) Nuclei and cell debris were pelleted by centrifugation (1000 g, 10 min). The resulting post-nuclear extracts were then ultracentrifuged at 4 uC in a Hitachi CP65b centrifuge (195 480 g, 10 min). The supernatant representing the cytosolic fraction was adjusted to 0.5 % Triton X-100, whilst the pellet was resuspended in lysis buffer [20 mM HEPES (pH 8.0), 0.5 % Triton X-100, 150 mM NaCl] to obtain the vesicular fraction. The amount of CA protein in the cytosolic fraction was determined by p24 ELISA (the detection limit of ELISA for the p24 antigen was 7.8 pg ml 21 , as provided by the manufacturer; ZeptoMetrix Corp.) according to the manufacturer's protocol. on virus release was also monitored by p24 ELISA as the amount of CA protein in cell-culture supernatants of CEM/LAV-1 cells treated with or without sc-222229.
Quantitative analysis of HIV-1 reverse transcription during acute infection. The analysis of de novo-synthesized HIV-1 cDNA was performed as follows. Briefly, TZM-bl cells (1610 6 ) were infected with the Ser 16 -phosphorylation-defective virus or ERK2-packagingdefective virus and incubated for 4 h. The cells were washed with PBS(2), further incubated for 20 h at 37 uC, washed again with PBS(2) and finally incubated for 5 min at 37 uC in PBS(2) containing 0.25 % trypsin. After trypsinization, the cells were washed twice with PBS(2) and then digested in 200 ml digestion buffer [10 mM Tris/HCl (pH 8.0), 150 mM NaCl, 10 mM EDTA, 0.1 % SDS, 100 mg proteinase K ml 21 ] for 2 h at 50 uC. After digestion, the proteinase K was heat inactivated for 10 min at 95 uC. De novo HIV-1 cDNA was quantified using the protocol of Ikeda et al. (2004) .
Determination of HIV-1 infectivity. HIV-1 infection was quantified using TZM-bl cells, which express the luciferase and b-galactosidase genes under the control of the HIV-1 long terminal repeat promoter (Derdeyn et al., 2000) . TZM-bl cells (4610 5 ) were incubated with the Ser 16 -phosphorylation-defective virus, ERK2-packaging-defective virus or control virus with 20 mg DEAE dextran ml 21 for 2 h at 37 uC, and then cultured in medium (200 ml) for 48 h. The cells were fixed, and the HIV-1 infection of TZM-bl cells was determined by measuring the luciferase activity in cell lysates.
Preparation of HIV-1 CA cores and in vitro uncoating assay.
The CA cores of the control HIV LAV-1 or the virus produced from CEM/LAV-1 cells incubated with 100 nM sc-222229 were purified in accordance with the method of Auewarakul et al., (2005) with some modifications. The cores were designated CA core wt and core sc , respectively. Briefly, 3 ml purified cell-free viruses was overlaid on a discontinuous sucrose density gradient. The gradient was composed of 1 ml 50 % sucrose at the bottom and 1 ml 10 % sucrose containing 0.1 % Igepal CA-630 on the top. The overlaid gradient was then centrifuged at 100 000 for 2 h at 4 uC. The pellets containing viral cores were then resuspended in uncoating assay buffer [50 mM NaH 2 PO 4 (pH 7.2), 150 mM NaCl, 200 mM sodium orthovanadate] and pooled. In contrast, for ALP treatment, the pellets containing viral cores were resuspended in ALP assay buffer [50 mM Tris/HCl (pH 7.2), 150 mM NaCl[. The CA cores were quantified by measuring the HIV-1 p24 antigen with a p24 ELISA.
An in vitro uncoating assay was performed as described previously (Misumi et al., 2010) . The control CA core wt and core sc were purified as described above. Each purified CA core (2 ng) was resuspended in uncoating assay buffer and incubated with or without 0.114 mg GST-Pin1 ml 21 or 0.114 mg GST ml 21 at 37 uC for 1 h. Each core suspension was then diluted in 5 ml uncoating assay buffer and centrifuged at 100 000 g for 2 h at 4 uC. The extent of CA release was quantified by a p24 ELISA, where the undissociated cores were pelleted and the dissociated CA protein was in the supernatant after ultracentrifugation. The relative percentage of disassembly efficiency (RPDE) was given by RPDE (%)51006(CAs/CA T )/(CA SCONT /CA TCONT ), where CA S is the concentration of the CA protein in the supernatant in the disassembly experiments using the CA core sc with or without GST-Pin1, CA T is the concentration of total CA protein in the supernatant plus pellet in the disassembly experiments using the CA core sc , CA SCONT is the concentration of the CA protein in the supernatant in the control experiment of the CA core wt with or without GST-Pin1, and CA TCONT is the concentration of total CA protein in the supernatant plus pellet in the control experiment using the CA core wt . The RPDE in the control experiment using CA core wt with GST-Pin1 was set as 100 %.
Another fraction of the purified CA core wt and CA core sc was incubated with ALP (final concentration 0.345 mg ml 21 ) or heat-denatured ALP (final concentration 0.345 mg ml 21 ) at 37 uC for 2 h. The resulting CA cores were further incubated with 0.114 mg GST-Pin1ml 21 at 37 uC for 1 h. The RPDE was analysed in the same way.
Suppression of ERK2 packaging by siRNA. To suppress ERK2 packaging inside virions, CEM/LAV-1 cells (5610 5 ) were electroporated with 1 mM validated Stealth ERK2 siRNA (Life Technologies Corp., sense 59-CCGAAGCACCAUUCAAGUUCGACAU-39, antisense 59-AUGUCGAACUUGAAUGGUGCUUCGG-39) and 100 nM control siRNA (voltage, 1500 V; width, 10 ms; and pulses, 3; Neon Electroporation System, Invitrogen). After 24 h, the cells were washed and cultured for 48 h with antibiotic-free RPMI 1640 containing 10 % FCS. The virus-containing supernatant was collected 72 h after transfection and purified by anti-CD45 immunoaffinity depletion of microvesicles. The lysates of ERK2-siRNA-treated CEM/LAV-1 cells and virus preparations purified by anti-CD45 immunoaffinity depletion of microvesicles were analysed by Western blotting using anti-CD45 antibody, anti-ERK2 antibody, anti-ERK1 antibody, antiphosphorylated ERK2 antibody (dual phospho-Thr 185 /Tyr 187 ) and HIV-positive plasma, as described above, and anti-actin antibody (Oncogene Research Products).
